Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Medicare Payment Policy, Value-Based Care, and the Importance of Quality Measurement in Dermatology

Description

The speaker explains Medicare physician payment and why dermatologists must engage in quality measurement and value-based care. She describes how CPT and RUC define services and work effort, while CMS assigns payment under a budget-neutral fee-for-service system that has not kept up with inflation. Because policymakers want to move away from fee-for-service toward value-based care, measures like MIPS, MVPs, ACOs, capitation, and bundled payments are increasingly used to assess quality over cost. She stresses that physicians should help define meaningful quality measures, ensure easy data submission, and insist on risk adjustment so doctors treating sicker or more complex patients are not unfairly penalized. Using psoriasis and Mohs surgery examples, she argues that raw costs alone can be misleading because better care for severe disease often costs more. She also highlights Dataderm as a tool to capture and analyze dermatology data, support improvement, and tell the specialty’s story. Overall, her message is that dermatologists must own their data, shape payment models, and push for quality measures tied to the same disease as the cost measure to accurately demonstrate value and improve patient care.

View more

Conclusions

Medicare physician payment has lagged far behind practice cost inflation, creating sustained reimbursement pressure for physicians.
Fee-for-service payment is driven by coding, valuation, and budget-neutral redistribution rather than by physicians directly setting prices.
Value-based care is being adopted broadly across Medicare, Medicaid, and private payers, with quality-over-cost as the central goal.
Quality measures are only useful if they are meaningful to clinicians and patients and can be reported without adding excessive burden to practice workflow.
Alternative payment models should be designed by physicians so they preserve financial stability, avoid denying necessary care, and penalize true outliers rather than average practice.
Risk adjustment is essential because treating more severe or complex patients should not be mistaken for worse performance or lower value.
Quality and cost measures should be paired within the same disease state, because comparing outcomes in one condition to costs in another can produce misleading conclusions.
Dermatology needs to demonstrate its value by showing that specialists improve severe disease, restore function, and help patients return to normal life sooner.
Real-world data registries like DataDerm can help dermatologists tell their story, measure outcomes, and support continuous quality improvement.
MIPS and emerging MVP/APM pathways are pushing dermatology toward reporting systems that will increasingly emphasize quality measurement, cost awareness, and data-driven advocacy.

American Medical Association. Medicare physician payment continues to fall further behind practice cost inflation. Updated Jan. 2026.
AAD MACRA Resource Center: https://www.aad.org/practice-tools/macra